Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some general statements (brand/active ingredient, class, broad use concepts, and general dosing/interaction checking) are plausible, but multiple claims are not supported by the provided label excerpts, and the response omits boxed warning content relevant to VRAYLAR (mortality in elderly dementia-related psychosis, cerebrovascular events) and suicide-related monitoring/possible discontinuation guidance.
Category Scores
Accurate Statements
Vraylar is a brand of cariprazine capsules.
Supported by provided label metadata: Drug VRAYLAR® with active ingredient cariprazine.
Cariprazine is an antipsychotic medicine.
Supported by provided label context referring to antipsychotic drugs and VRAYLAR as an antipsychotic in Sections 5.1 and 8.5.
Vraylar dosing depends on how a patient responds.
Supported only in a general sense by the provided label excerpt 8.5 stating dose selection should be cautious and start low in elderly; however, responsiveness-based titration is not explicitly provided in the excerpts. (Marked as partially supported/weak support.)
A pharmacist or prescriber can check interactions specific to a patient’s medication list.
Not supported or contradicted by provided excerpts; however it does not conflict with any label content. (Evaluated as non-contradictory/unspecified rather than explicitly supported.)
Unsupported Statements
Cariprazine is used to treat certain mood and psychotic disorders.
The provided label excerpts do not describe indications or specific disorders other than dementia-related psychosis being not approved.
Cariprazine is used for schizophrenia.
Not supported by the provided label excerpts.
Cariprazine is used for bipolar-spectrum conditions.
Not supported by the provided label excerpts.
Cariprazine works by affecting dopamine and serotonin signaling in the brain.
Mechanism of action is not present in the provided label excerpts.
Cariprazine helps with symptoms tied to psychosis.
Not supported by the provided label excerpts.
Cariprazine helps with symptoms tied to mood regulation.
Not supported by the provided label excerpts.
Common side effects of Vraylar include nausea.
The provided label excerpts only mention adverse reactions associated with boxed warnings (increased mortality, suicidal thoughts/behaviors, cerebrovascular events) and do not list nausea as a common side effect.
Common side effects of Vraylar include sleep problems.
Not supported by the provided label excerpts.
Common side effects of Vraylar include movement-related effects.
Not supported by the provided label excerpts.
Common side effects of Vraylar include changes related to appetite or weight.
Not supported by the provided label excerpts.
Vraylar dosing depends on the condition being treated.
The provided excerpts do not specify dosing by indication.
Vraylar capsules come in different strengths.
Strengths are not described in the provided excerpts.
Vraylar dosing may start lower and adjust over time.
The provided label excerpt 8.5 supports starting at the low end in elderly with caution, but does not support general titration over time across populations/indications.
Drug interactions for Vraylar depend on what other medications a patient takes.
The provided excerpts do not include drug interaction information.
Patients often look for interactions between cariprazine and antidepressants.
Not supported by the provided label excerpts (no interaction table/content, and 'often look for' is not label-based).
Patients often look for interactions between cariprazine and other antipsychotics.
Not supported by the provided label excerpts.
Patients often look for interactions between cariprazine and seizure medications.
Not supported by the provided label excerpts.
Patients often look for interactions between cariprazine and drugs that affect liver enzymes.
Not supported by the provided label excerpts.
Vraylar is often priced like a specialty branded medicine.
Pricing information is not included in the provided prescribing information excerpts.
Contradictions
Low
AI Statement
Cariprazine is used to treat certain mood and psychotic disorders.
Label Reference
Provided excerpts only indicate lack of approval for dementia-related psychosis (5.1) and increased risk/monitoring in specific contexts; they do not confirm approved indications. No direct contradiction is identifiable from provided text.
Important Omissions
Boxed warning content: increased all-cause risk of death in elderly patients with dementia-related psychosis and that VRAYLAR is not approved for this indication.
Importance:
High
Warnings about cerebrovascular adverse reactions including stroke in elderly patients with dementia-related psychosis and that VRAYLAR is not approved for this indication.
Importance:
High
Boxed warning-related monitoring for suicidal thoughts and behaviors in children, adolescents, and young adults (especially during initial months and dose changes) and consideration of changing/discontinuing regimen in persistently worse depression or emergent suicidal thoughts/behaviors.
Importance:
Moderate
Geriatric use caution: clinical trials did not include sufficient patients ≥65 to determine response differences; start at low end reflecting decreased hepatic/renal/cardiac function and concomitant disease/drug therapy.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response omits boxed warning and key safety guidance in the provided label excerpts (elderly dementia-related psychosis mortality; cerebrovascular events/stroke in that population; suicidal thoughts/behaviors monitoring in young patients; geriatric dosing caution). Other claims about side effects and interactions are largely unsupported by the provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Major safety omissions: the response does not include the provided boxed warnings and associated 'not approved' statements for dementia-related psychosis, nor the suicidal thoughts monitoring guidance.
Suggested Improvement
Include the boxed-warning and key warnings content from Sections 5.1, 5.2, 5.3 and the geriatric dosing caution from Section 8.5; limit claims to what is supported by the provided label excerpts (or supply the missing label sections for indications, dosing, strengths, side effects, and drug interactions).